Event
Immunotherapy and Newly Diagnosed GBM: Phase 1B Results and 2b Trial Overview
presented by Subcortical Surgery Group
49 others would like to attend.
Register Now
Tuesday, May 4, 2021 6 PM
-
7 PM
America/New_York
Event info
Special Look at Phase 1b Imvax Study to Assess the Safety & Efficacy of IGV-001
- Explore highest exposure cohort yielded significantly higher pro- inflammatory cytokine serum levels significant improvement
in both PFS and OS over historical controls - Study methylated subgroup manifesting a 3-fold improvement in mPFS with mOS not yet reached
- Deep dive with data lock, highest exposure cohort exhibiting significant improvement in both PFS and OS over
historical controls
An Overview of Emerging Therapeutic Targets
- Examine the current treatment options and emerging targeted therapies
- If targeted therapies show limited efficacy as single agents, can the combination of several targeted therapies be of benefit
to GBM patients? - Additional research is urgently required to identify therapeutic targets in GBM: How can the industry design novel therapeutic strategies for the treatment of GBM?
49 others would like to attend.
Register Now
Login to view comments.
Click here to Login